No posts to display
News
Zai Lab’s AUGTYRO approved in China for patients with ROS1-positive NSCLC
The National Medical Products Administration (NMPA) in China has approved Zai Lab's New Drug Application (NDA) for AUGTYRO™ (repotrectinib) for the treatment of adult...
AbbVie and Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders
AbbVie and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise...
UK and Swiss consortium to apply innovative technologies to lower cost of manufacturing cell...
A UK and Swiss consortium has been awarded over £750,000 from the national innovation agencies Innovate UK and Innosuisse to integrate new digitisation and...
